Literature DB >> 2537065

Peripheral neuropathy as an early marker of AL amyloidosis.

M A Duston1, M Skinner, J Anderson, A S Cohen.   

Abstract

Fifty-one of 146 patients with primary amyloid deposits of light-chain origin (AL) examined between 1972 and 1986 were found to have peripheral neuropathy as part of their systemic amyloidosis. Peripheral neuropathy was the presenting symptom in 11 patients, and it was a later symptom or an incidental physical examination finding at the time of amyloid workup in 40 additional patients. The median duration of time from first symptom to the diagnosis of primary amyloidosis was longer in those whose first symptom was neuropathy (48 months vs 12 months). In addition, survival time after diagnosis for these patients was significantly longer (at least 35 months vs 16 months). Peripheral neuropathy is not an uncommon symptom of primary amyloidosis and may mark the onset of the disease process years before infiltration of vital structures of the heart, kidneys or gastrointestinal tract leads to failure and a subsequent downhill course. Appreciating amyloid disease at this early stage may widen the potential therapeutic window.

Entities:  

Mesh:

Year:  1989        PMID: 2537065

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.

Authors:  Andrew J Cowan; Martha Skinner; David C Seldin; John L Berk; David R Lichtenstein; Carl J O'Hara; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.

Authors:  Jennifer Ellis Ward; Ruiyi Ren; Gianluca Toraldo; Pam Soohoo; Jian Guan; Carl O'Hara; Ravi Jasuja; Vickery Trinkaus-Randall; Ronglih Liao; Lawreen H Connors; David C Seldin
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

Review 3.  Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis.

Authors:  Christopher E Jensen; Mirnela Byku; Gerald A Hladik; Koyal Jain; Rebecca E Traub; Sascha A Tuchman
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

4.  Patterns of neuropathy and autonomic failure in patients with amyloidosis.

Authors:  Annabel K Wang; Robert D Fealey; Tonette L Gehrking; Phillip A Low
Journal:  Mayo Clin Proc       Date:  2008-11       Impact factor: 7.616

Review 5.  Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review.

Authors:  Irina Adriana Andrei; Thierry Kuntzer; Johannes Alexander Lobrinus; Arnaud Jaccard; Pascal Zufferey
Journal:  Clin Rheumatol       Date:  2014-09-18       Impact factor: 2.980

6.  Autonomic Neuropathy and Albuminocytologic Dissociation in Cerebrospinal Fluid As the Presenting Features of Primary Amyloidosis: A Case Report.

Authors:  Jingjing Li; Yi Li; Hongbing Chen; Shihui Xing; Huiyu Feng; Dawei Liu; Dilong Wang; Jinsheng Zeng; Yuhua Fan
Journal:  Front Neurol       Date:  2017-07-26       Impact factor: 4.003

7.  Gastrointestinal Tract Amyloidosis Presenting With Pneumatosis Intestinalis.

Authors:  Vikram Raghunathan; David Louis; Baldeep Wirk
Journal:  J Clin Med Res       Date:  2017-05-22

Review 8.  An update on the diagnosis and management of the polyneuropathy of POEMS syndrome.

Authors:  Federica Cerri; Yuri Matteo Falzone; Nilo Riva; Angelo Quattrini
Journal:  J Neurol       Date:  2018-09-27       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.